Quantcast
Last updated on April 19, 2014 at 9:20 EDT

UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities

January 10, 2013

UPM Pharmaceuticals improves its pre-formulation methods through its newly purchased TA Instruments Q20 Auto MDSC and TA Instruments Q50 TGA. These allow the formulation development company to assure clients of even better quality research and results worthy of their investment.

Baltimore, MD (PRWEB) January 09, 2013

UPM Pharmaceuticals announced today that it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA (Thermogravimetric Analyzer). These pieces of equipment greatly enhance the formulation development company´s ability to provide comprehensive pre-formulation studies, as well as support analytical testing of challenging formulations such as poorly soluble compounds.

UPM´s President, Jim Gregory, said, “UPM sees these new pieces of analytical equipment combined with our already highly qualified and experienced analytical team as a powerful combination for our clients who are trying to make the best and most cost effective decisions about investment of precious research funds. And further is looking for a partner that can perform the latest and best analysis with the most reliable equipment available in the pre-formulation stage of development.”

UPM Pharmaceuticals®, Inc. is a Baltimore-based contract development and manufacturing organization providing customized formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients.

Fully appreciating that time-to-market is critical, UPM offers remarkably flexible, affordable, and rapid outsourcing services designed to meet clients´ specific development and manufacturing needs. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries, and academic institutions who have a focus on clinical studies.

About UPM Pharmaceuticals

UPM Pharmaceuticals, Inc. is a Baltimore-based, independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. They provide high quality pharmaceutical drug development services including formulation development, cGMP manufacturing, analytical methods development and stability testing. They are characterized by the quality, speed and thoroughness with which they complete all their projects. UPM´s clients enjoy service that is customized and fast with total quality management characteristic of a customer-focused business. Their history includes successful collaborative interactions with virtual to multi-million dollar companies providing them with customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets.

To learn more about UPM, please visit the Web site at http://www.upm-inc.com/

UPM Pharmaceuticals is a registered U.S. trademark.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebupm-inc/formulation-development/prweb10301311.htm


Source: prweb